Tango Therapeutics to Participate in Upcoming Investor Conferences
Tango Therapeutics (NASDAQ: TNGX), a clinical-stage biotechnology company, announced that its CEO, Barbara Weber, will participate in two investor conferences this November.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Tango Therapeutics (NASDAQ: TNGX), a clinical-stage biotechnology company, announced that its CEO, Barbara Weber, will participate in two investor conferences this November. The first event is the H.C. Wainwright 3rd Annual Precision Oncology Conference on November 14 at 11:00 AM ET, followed by the Jefferies London Healthcare Conference on November 15 at 10:20 AM GMT. Both presentations will be available via live webcast on the company’s website, with replays accessible for 90 days.
Details
News Market Reaction – TNGX
The recorded move for TNGX in the trading session of this news was +1.70%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
BOSTON, Nov. 07, 2022 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX), a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision cancer medicines, today announced that Barbara Weber, M.D., President and Chief Executive Officer of Tango Therapeutics, is scheduled to participate in the following upcoming investor conferences in November.
H.C. Wainwright 3rd Annual Precision Oncology Conference
Date: Monday, November 14, 2022
Time: 11:00 AM ET
Location: Virtual
Jefferies London Healthcare Conference
Date: Tuesday, November 15, 2022
Time: 10:20 AM GMT
Location: London, United Kingdom
A live webcast of the presentations will be available under the "Events & Presentations" tab on the “Investors” page on the Company's website on the day of the event. A replay of the webcast will be archived on the Company's website for approximately 90 days following the presentation.
About Tango Therapeutics
Tango Therapeutics is a clinical-stage biotechnology company dedicated to discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. Using an approach that starts and ends with patients, Tango leverages the genetic principle of synthetic lethality to discover and develop therapies that take aim at critical targets in cancer. This includes expanding the universe of precision oncology targets into novel areas such as tumor suppressor gene loss and their contribution to the ability of cancer cells to evade immune cell killing. For more information, please visit www.tangotx.com.
Investor Contact:
Sam Martin/Andrew Vulis
Argot Partners
tango@argotpartners.com
Media Contact:
Joshua R. Mansbach
Argot Partners
tango@argotpartners.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.